Recon: FDA denies Atara’s cell therapy for rare transplant complication; Lilly CEO looks for ‘common cause’ with Trump administration

ReconReconApproval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)